RegenXBio Inc. ($RGNX) announced an update on their ongoing clinical study. RegenXBio Inc. is conducting a Phase 3 clinical study titled ‘A Phase ...
Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute ...
Building Futures Pediatric Therapy hosted their annual children’s lighted bike parade Friday, December 12, 2025 ...
Proton therapy, previously used in pediatric cases to minimize treatment-related side effects, has now shown promise for adults.
The U.S. Food and Drug Administration has approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant ...
The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to than 12 years with hereditary ...
BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.
BioCryst Pharmaceuticals has won U.S. Food and Drug Administration approval for the expanded use of its Orladeyo hereditary-angioedema drug for children ages 2 through 11.
ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides ...
Through the five-year study, researchers are testing approaches that can make high-quality mental health treatment easier for ...
2d
Country Cares for Kids Radiothon helps bring joy to young patients at UC Davis Children's Hospital
Our radio partners at KNCI 105.1 FM are partnering with Children's Miracle Network to help local kids and their families.
NanOlogy, LLC, a private clinical-stage oncology company, is pleased to announce its drug development program aimed at transformin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback